Skip to main content
High RiskFDAfda-Z-0217-2024ELECTRICAL SHOCK

LEAD 3387S-40 STIMLOC DBS, Model Number 3387S-40. Electrical implantable device.

Units Affected
14
Recall Date
May 27, 2022
Issuing Agency
Hazard
Electrical Shock

FDA Recall Notice

Source: U.S. Food and Drug Administration (FDA) — official FDA notice for recall FDA-Z-0217-2024.

There are a small number of units of the DBS Lead with StimLoc kit (3387S-40) due to a discrepancy in the Use By Date (UBD) printed on the outer packaged kit label versus the UBD printed on the individual product label.

Corrective Action (per FDA)

Source: U.S. Food and Drug Administration (FDA) — official FDA notice for recall FDA-Z-0217-2024.

Recall ongoing. Follow firm instructions.

✅ What you should do

  1. Stop using the product if you own it.
  2. Check the model number, lot code, or sell-by date against the recall notice above.
  3. Contact Medtronic Neuromodulation or the retailer where you bought it for a refund, replacement, or repair.
  4. For the most current official instructions, visit the FDA recall page.
  5. If you've been hurt by this product, report the incident to FDA.

Consumer Contact (per FDA)

Source: U.S. Food and Drug Administration (FDA) — official FDA notice for recall FDA-Z-0217-2024.

Medtronic Neuromodulation

FDA

About the U.S. Food and Drug Administration

The FDA regulates drugs, medical devices, food, cosmetics, and tobacco. Adverse event reports and recall notices are the main public safety signal.

Visit FDA.gov →

📣 Report a food, supplement, or cosmetic problem to the FDA

If you had a reaction, found contamination, or experienced a labeling problem with this product, report it to the FDA. The agency uses consumer reports to track emerging safety signals and trigger recalls.

How to report to FDAFile a report at FDA

Medtronic Neuromodulation Recall FAQ

Medtronic Neuromodulation is the subject of a medical implants safety report: LEAD 3387S-40 STIMLOC DBS, Model Number 3387S-40. Electrical implantable device.. The notice was published on May 27, 2022 by the U.S. Food and Drug Administration (FDA). Approximately 14 units are potentially affected.